We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.64, which surpassed the Zacks Consensus Estimate by 3.13%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 9.36%.
ALGN’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.01 billion, which suggests 1.1% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.77 per share, which implies a 6.1% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q3 Earnings
Estimates for earnings have moved south 1 cent to $2.77 per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
Factors Shaping ALGN’s Q3 Performance
Clear Aligner
The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First, the Invisalign Palatal Expander and the Invisalign Mandibular Advancement with Occlusal Blocks (“MOAB”).
Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter.
The Zacks Consensus Estimate for Clear Aligner revenues indicates 3.6% year-over-year growth.
Imaging Systems & CAD/CAM Services (Systems and Services)
Within this segment, revenues are likely to have faced a negative impact from continued challenges in the capital equipment market with higher interest rates and increased macro uncertainty. However, in the previous quarter, scanner placements to new doctors reached a record level and increased double digits year over year, driven by continued adoption of iTero Lumina. We expect this trend to have continued in the to-be-reported quarter as well.
exocad achieved strong revenue growth, reinforcing the company’s strategy to integrate orthodontics and restorative dentistry within a customer and patient-centric digital platform. We expect this trend to have persisted in the third quarter as well.
The company introduced two new Align Digital Platform capabilities to enhance patient engagement, treatment planning and workflow efficiency. Combined with the Invisalign Palatal Expander platform and customized 3D-printed features, these innovations support a more integrated digital workflow from imaging and diagnosis to treatment delivery. We expect the development to have contributed to the company’s top-line growth.
The Zacks Consensus Estimate for the segment’s revenues implies a decrease of 8% on a year-over-year basis.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Align Technology has an Earnings ESP of -2.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Align Technology to Report Q3 Earnings: What's in the Cards?
Key Takeaways
Align Technology, Inc. (ALGN - Free Report) is set to release third-quarter 2026 results on Oct. 28, after the closing bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.64, which surpassed the Zacks Consensus Estimate by 3.13%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 9.36%.
ALGN’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.01 billion, which suggests 1.1% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.77 per share, which implies a 6.1% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q3 Earnings
Estimates for earnings have moved south 1 cent to $2.77 per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
Factors Shaping ALGN’s Q3 Performance
Clear Aligner
The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First, the Invisalign Palatal Expander and the Invisalign Mandibular Advancement with Occlusal Blocks (“MOAB”).
Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter.
The Zacks Consensus Estimate for Clear Aligner revenues indicates 3.6% year-over-year growth.
Labcorp Holdings Inc. Price and EPS Surprise
Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote
Imaging Systems & CAD/CAM Services (Systems and Services)
Within this segment, revenues are likely to have faced a negative impact from continued challenges in the capital equipment market with higher interest rates and increased macro uncertainty. However, in the previous quarter, scanner placements to new doctors reached a record level and increased double digits year over year, driven by continued adoption of iTero Lumina. We expect this trend to have continued in the to-be-reported quarter as well.
exocad achieved strong revenue growth, reinforcing the company’s strategy to integrate orthodontics and restorative dentistry within a customer and patient-centric digital platform. We expect this trend to have persisted in the third quarter as well.
The company introduced two new Align Digital Platform capabilities to enhance patient engagement, treatment planning and workflow efficiency. Combined with the Invisalign Palatal Expander platform and customized 3D-printed features, these innovations support a more integrated digital workflow from imaging and diagnosis to treatment delivery. We expect the development to have contributed to the company’s top-line growth.
The Zacks Consensus Estimate for the segment’s revenues implies a decrease of 8% on a year-over-year basis.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Align Technology has an Earnings ESP of -2.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.